Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial.
Marla Lipsyc-SharfFang-Shu OuMatthew B YurgelunDouglas A RubinsonDeborah SchragShaker R DakhilPhilip J StellaDouglas J WecksteinDonald B WenderMeredith FaggenTyler J ZemlaErica N HeyingSamantha R SchuetzStephanie NobleJeffrey A MeyerhardtTanios Bekaii-SaabCharles S FuchsKimmie NgPublished in: The oncologist (2022)
In this prematurely discontinued trial, there was no significant difference in the primary endpoint of PFS between CBI and CI. There was a statistically significant improvement in OS in favor of CBI compared with CI. Further investigation of CBI for the treatment of irinotecan-refractory mCRC is warranted.Clinical Trial Registration: NCT02292758.